![]() |
½ÃÀ庸°í¼
»óÇ°ÄÚµå
1427023
Á¦¾à »ê¾÷ÀÇ ÁÖ¿ä 5°³ ¼ºÀå ±âȸ(2024³â)Top 5 Growth Opportunities for the Pharmaceutical Industry, 2024 |
±â¼úÀ» È°¿ëÇÑ ÆÄÆ®³Ê½ÊÀ¸·Î Á¤¹Ð Á¾¾çÇÐ, Èñ±ÍÁúȯ, ºñ¸¸ ºÐ¾ßÀÇ ½Å¾à °³¹ß ÃËÁø
2024³â »ý¸í°úÇÐ(LS) ¾÷°è´Â Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ÁýÁßµµ°¡ ³ô¾ÆÁú °ÍÀ¸·Î ¿¹»óµÇ¸ç, LS ±â¾÷µéÀº ¿À¹Í½º ±â¹Ý ¿¬±¸ ¿ª·®À» °ÈÇÏ°í AI¿Í ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º¸¦ µµÀÔÇÏ¿© °³ÀÎ ¸ÂÃãÇü Ä¡·á¹ýÀ» ´õ¿í ¸¹ÀÌ ¹ß°ßÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. Èñ±ÍÁúȯ, ºñ¸¸, ¾Ï¿¡ ´ëÇÑ ½Å¾à°³¹ß Çõ½ÅÀ» Áö¿øÇϱâ À§ÇØ Á¦¾àȸ»ç¿Í ±â¼ú °ø±Þ¾÷ü¿ÍÀÇ ÆÄÆ®³Ê½ÊÀÌ ´õ¿í È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌÀü¿¡´Â ¾à¹° °³¹ßÀÌ ºÒ°¡´ÉÇß´ø Ç¥Àû¿¡ ´ëÇÑ Ç¥ÀûÈ °¡´É¼ºÀº ¸®º¸ÇÙ»ê(RNA) ±â¼ú, ´Ü¹éÁú ºÐÇØ(PROTAC), Ç×ü °øÇÐ ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¿Í ÆÄÆ®³Ê½ÊÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. Á¤¹Ð Á¾¾çÇÐÀº Áß¿äÇÑ ÁßÁ¡ ºÐ¾ß·Î, ´õ ¸¹Àº ¹Î°ü ÆÄÆ®³Ê½ÊÀ» ±¸ÃàÇÔÀ¸·Î½á °ÈµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à»ç, ÀÓ»ó½ÃÇè¼öŹ±â°ü(CRO), µðÁöÅÐ Ä¡·áÁ¦(DTx), Áø´Ü ±â¾÷, ¸®¾ó¿ùµå¿¡ºñ´ø½º(RWE) ¼Ö·ç¼Ç °ø±Þ¾÷ü, Â÷¼¼´ë ¿°±â¼¿ºÐ¼®(NGS) ±â¾÷, ÀÇ·á±â±â Á¦Á¶¾÷ü µî ¾÷°è Àü¹ÝÀÇ Çù¾÷ÀÌ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀΰøÁö´ÉÀÇ µµÀÔÀº ½Å¾à °³¹ß ¹× Àç»ç¿ë °¡¼ÓÈ, ÀÓ»ó½ÃÇèÀÇ ¹ÎÁÖÈ ¹× ¼³°è, RWD ºÐ¼®, Á¦Á¶ ÀÚµ¿È, °ø±Þ¸Á Åõ¸í¼ºÀ» °ÈÇÏ¿© ȯÀÚ, ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü ¹× Á¦¾à ¾÷°è Àüü¿¡ ÇýÅÃÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
Tech-enabled Partnerships Propelling Drug Discovery and Development in Precision Oncology, Rare Diseases, and Obesity
In 2024, the life science (LS) industry's focus on precision health will intensify. LS companies will augment their omics-based research capabilities and increasingly deploy AI and bioinformatics to discover personalized therapies. Partnerships between pharmaceutical companies and technology vendors will multiply, to support innovation in drug discovery for rare diseases, obesity, and oncology.
The possibility of targeting previously undruggable targets will drive investments and partnerships in ribonucleic acid (RNA) technology, protein degradation (PROTAC), and antibody engineering technologies. Precision oncology is a vital area of focus, reinforced by the establishment of more public-private partnerships. There will be an increase in cross-industry collaboration between pharmaceutical companies, contract research organizations (CROs), digital therapeutics, diagnostic companies, real-world evidence (RWE) solution vendors, next-generation sequencing (NGS) companies, and medical device players. The implementation of artificial intelligence will intensify for accelerated drug discovery and drug repurposing, clinical trial democratization and design, RWD analysis, manufacturing automation, and supply chain transparency, with resulting benefits extending to patients, healthcare providers, and the pharmaceutical industry overall.